NCT06333483Active, not recruitingPhase 1
A Single-Arm, Open-Label, Phase 1 Study to Determine the Safety, Tolerability and Preliminary Efficacy of Obecabtagene Autoleucel in Patients with Severe, Refractory Systemic Lupus Erythematosus
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Jul 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 6 Nov 2023
- Start date
- 13 Jun 2024
- Lead sponsor
- Autolus Limited
- Diseases
- Lupus (SLE)
- EU CT number
- 2023-508236-60-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 6
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Active, not recruiting |
| Hospital Universitario Y Politecnico La Fe Coordinator of this site? Confirm its status | Valencia | Spain | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.